CoChat
Sign Up
Cited by 44Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrovascular and genetic disorders

Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42

Open access
Stenset, V., Johnsen, L., Kocot, D., Negaard, A., Skinningsrud, A., Gulbrandsen, P., Wallin, A., Fladby, T.·2006·Neurology
DOI 10.1212/01.wnl.0000234030.77831.5a
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To analyze a putative relationship between white matter lesions (WMLs), risk factors for WMLs, and Alzheimer disease (AD) as measured with the surrogate marker CSF Abeta42. METHODS: The authors analyzed effects of acquired risk factors for cerebrovascular disease and WMLs on AD as measured with an intermediate marker, CSF Abeta42. A total of 127 consecutive patients with subjective memory impairment (mean age 66 years; 57 women) investigated at a university-based memory clinic had brain MRI scans. WMLs were rated on a 12-point scale with a semiquantitative procedure. They used path analysis with established and possible risk factors for WMLs and for reduced CSF Abeta42 (age, hypertension, hyperhomocysteinemia, hypercholesterolemia, APOE-epsilon4) as variables. RESULTS: The WML score was 1.5 points higher (p < 0.05) in hypertensive than in nonhypertensive patients and 1.9 points higher (p < 0.05) in patients with hyperhomocysteinemia than in those with normal homocysteine levels. Hypercholesterolemia increased the probability of low CSF Abeta42 levels by 0.2 (p < 0.05). For each point increase in WML score, the probability of low CSF Abeta42 levels increased by 0.03 (p < 0.05). APOE-epsilon4 was associated with reduced CSF Abeta42 (p < 0.01). CONCLUSION: Both hypercholesterolemia and white matter lesions may contribute to low CSF Abeta42 by independent mechanisms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000234030.77831.5a

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most cross-sectional studies reported an association between WMH and amyloid markers (CSF Aβ42 or Aβ PET) but not tau markers.

    “Most cross‐sectional studies reported an association between WMH and amyloid markers (either CSF Aβ42 or Aβ deposition on PET) but not tau markers. 55 , 56 , 57 , 58 , 59”

    From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [55]

    The Paper I summary reports an association between MRI-rated white matter lesions and low CSF Aβ42 in memory-clinic patients, supporting this study as an example of the amyloid-marker finding. It does not report a comparison between white matter lesions and tau markers, so it does not support the “but not tau markers” part of the claim. This single study also cannot establish what most cross-sectional studies found. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 46 references couldn’t be matched to a known paper.

Research works printed but not linked: 139

  1. REFERENCES ANDREASEN N, BLENNOW K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005;107:165-173.
  2. R, MASSARO JM, WOLF PA et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol 2006;63:246-50.
  3. AWAD IA, JOHNSON PC, SPETZLER RF, HODAK JA. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke 1986;17:1090-7.
  4. BAEZNER H, BLAHAK C, POGGESI A et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008;70:935-42.
  5. BALES KR, VERINA T, DODEL RC et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-264.
  6. BASSER PJ, MATTIELLO J, LEBIHAN D. MR diffusion tensor spectroscopy and imaging. Biophys J 1994;66:259-267.
  7. BASSER PJ. Inferring microstructural features and the physiological state of tissues from diffusion-weighted images. NMR Biomed 1995;8:333-344.
  8. BAUM KA, SCHULTE C, GIRKE W, REISCHIES FM, FELIX R. Incidental white- matter foci on MRI in "healthy" subjects: evidence of subtle cognitive dysfunction. Neuroradiology 1996;38:755-60.
  9. BLENNOW K, DE LEON MJ, ZETTERBERG H. Alzheimer's disease. Lancet 2006;368:387-403.
  10. BLENNOW K, HAMPEL H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
  11. BRODAL P. The central nervous system: structure and function. 2nd ed. New York: Oxford University Press; 1998.
  12. BRONGE L, FERNAEUS SE, BLOMBERG M et al. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement Geriatr Cogn Disord 1999;10:89-96.
  13. BROOKMEYER R, JOHNSON E, ZIEGLER-GRAHAM K et al. Forecasting the global burden of Alzheimer's disease. Baltimore, USA: The Berkeley Electronic Press; 2007
  14. BUCKNER RL, SNYDER AZ, SHANNON BJ et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17.
  15. BUDDE MD, KIM JH, LIANG HF et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med 2007;57:688-695.
  16. BURNS JM, CHURCH JA, JOHNSON DK et al. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 2005;62:1870-6.
  17. CARMELLI D, DECARLI C, SWAN GE et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998;29:1177-1181.
  18. CATANI M, FFYTCHE DH. The rises and falls of disconnection syndromes. Brain 2005;128:2224-39.
  19. CATANI M, HOWARD RJ, PAJEVIC S, JONES DK. Virtual in vivo interactive dissection of white matter fasciculi in the human brain. Neuroimage 2002;17:77-94.
  20. CHALMERS K, WILCOCK G, LOVE S. Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathol Appl Neurobiol 2005;31:623- 31.
  21. CHARLTON RA, BARRICK TR, MCINTYRE DJ et al. White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology 2006;66:217-222.
  22. CHOI SJ, LIM KO, MONTEIRO I, REISBERG B. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study. J Geriatr Psychiatry Neurol 2005;18:12-19.
  23. CONCHA L, GROSS DW, WHEATLEY BM, BEAULIEU C. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. Neuroimage 2006;32:1090-1099.
  24. CONVIT A, DE LEON MJ, TARSHISH C et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging 1997;18:131-138.
  25. DE GROOT JC, DE LEEUW FE, OUDKERK M et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000;47:145- 51.
  26. DE GROOT JC, DE LEEUW FE, OUDKERK M et al. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071-6.
  27. DE LA MONTE SM. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 1989;25:450-459.
  28. DE LEEUW FE, DE KLEINE M, FRIJNS CJ, FIJNHEER R, VAN GIJN J, KAPPELLE LJ. Endothelial cell activation is associated with cerebral white matter lesions in patients with cerebrovascular disease. Ann N Y Acad Sci 2002;977:306-14.
  29. DE LEON MJ, MOSCONI L, BLENNOW K et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 2007;1097:114-145.
  30. DE REUCK J. The human periventricular arterial blood supply and the anatomy of cerebral infarctions. Eur Neurol 1971;5:321-34.
  31. DECARLI C, FLETCHER E, RAMEY V, HARVEY D, JAGUST WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50-5.
  32. DECARLI C, MURPHY DG, TRANH M et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-84.
  33. DEKOSKY ST, MAREK K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-834.
  34. DELANO-WOOD L, ABELES N, SACCO JM, WIERENGA CE, HORNE NR, BOZOKI A. Regional white matter pathology in mild cognitive impairment: differential influence of lesion type on neuropsychological functioning. Stroke 2008;39:794-9.
  35. DEO AA, GRILL RJ, HASAN KM, NARAYANA PA. In vivo serial diffusion tensor imaging of experimental spinal cord injury. J Neurosci Res 2006;83:801-810.
  36. DINIZ BS, PINTO JA, JR., FORLENZA OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2007;1-11.
  37. DRUBIN D, KOBAYASHI S, KELLOGG D, KIRSCHNER M. Regulation of microtubule protein levels during cellular morphogenesis in nerve growth factor-treated PC12 cells. J Cell Biol 1988;106:1583-1591.
  38. DU AT, SCHUFF N, AMEND D et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:441-447.
  39. DUBOIS B, FELDMAN HH, JACOVA C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
  40. EICHNER JE, DUNN ST, PERVEEN G, THOMPSON DM, STEWART KE, STROEHLA BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-495.
  41. FAGAN AM, MINTUN MA, MACH RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-9.
  42. FARRER LA, CUPPLES LA, HAINES JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
  43. FAZEKAS F, CHAWLUK JB, ALAVI A, HURTIG HI, ZIMMERMAN RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-6.
  44. FAZEKAS F, KLEINERT R, OFFENBACHER H et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683- 9.
  45. FELLGIEBEL A, MULLER MJ, WILLE P et al. Color-coded diffusion-tensor- imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging 2005;26:1193-1198.
  46. FERNANDO MS, SIMPSON JE, MATTHEWS F et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006;37:1391-1398.
  47. FLADBY T, MAEHLEN J. The amyloid and tau hypothesis in degenerative dementia. Tidsskr Nor Laegeforen 1999;119:976-9.
  48. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
  49. FORMICHI P, PARNETTI L, RADI E, CEVENINI G, DOTTI MT, FEDERICO A. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Eur J Neurol 2008;15:1252-5.
  50. FORSBERG A, ENGLER H, ALMKVIST O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007;29:1456-65.
  51. FRISONI GB, GALLUZZI S, PANTONI L, FILIPPI M. The effect of white matter lesions on cognition in the elderly--small but detectable. Nat Clin Pract Neurol 2007;3:620-7.
  52. GEORGE R, GRIFFIN JW. Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: the dorsal radiculotomy model. Exp Neurol 1994a;129:225-236.
  53. GEORGE R, GRIFFIN JW. The proximo-distal spread of axonal degeneration in the dorsal columns of the rat. J Neurocytol 1994b;23:657-667.
  54. GOLD G, KOVARI E, HOF PR, BOURAS C, GIANNAKOPOULOS P. Sorting out the clinical consequences of ischemic lesions in brain aging: a clinicopathological approach. J Neurol Sci 2007;257:17-22.
  55. GREEN MS, KAYE JA, BALL MJ. The Oregon Brain Aging Study: neuropathology accompanying healthy aging in the oldest old. Neurology 2000;54:105-13.
  56. GRUNDKE-IQBAL I, IQBAL K, TUNG YC et al. Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci 1986;83:4913-17.
  57. GUROL ME, IRIZARRY MC, SMITH EE et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-29
  58. HACHINSKI VC, POTTER P, MERSKEY H. Leuko-araiosis. Arch Neurol 1987;44:21-23.
  59. HANSSON O, ZETTERBERG H, BUCHHAVE P, LONDOS E, BLENNOW K, MINTHON L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
  60. HERZ J, BEFFERT U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci 2000;1:51-58.
  61. HESSE C, ROSENGREN L, VANMECHELEN E et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimer Dis 2000;2:199-206.
  62. HOLTZMAN DM, FAGAN AM, MACKEY B et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000;47:739-747.945.
  63. HUANG J, AUCHUS AP. Diffusion tensor imaging of normal appearing white matter and its correlation with cognitive functioning in mild cognitive impairment and Alzheimer's disease. Ann N Y Acad Sci 2007;1097:259-64.
  64. HUANG J, FRIEDLAND RP, AUCHUS AP. Diffusion tensor imaging of normal- appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol 2007;28:1943-1948.
  65. HUNT AL, ORRISON WW, YEO RA et al. Clinical significance of MRI white matter lesions in the elderly. Neurology 1989;39:1470-4.
  66. INZITARI D, MASCALCHI M. Leuko-araiosis: a reappraisal. I. CT studies. Ital J Neurol Sci 1990;11:241-248.
  67. INZITARI D. Age-related white matter changes and cognitive impairment. Ann Neurol 2000;47:141-3.
  68. IQBAL K, ALONSO ADEL C, CHEN S. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739:198-210.
  69. JACK CR, JR., PETERSEN RC, XU YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397- 1403.
  70. JENDROSKA K, POEWE W, DANIEL SE et al. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (Berl) 1995;90:461-66.
  71. JOKINEN H, KALSKA H, MANTYLA R et al. Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006;77:28-33.
  72. JONES DK, LYTHGOE D, HORSFIELD MA, SIMMONS A, WILLIAMS SC, MARKUS HS. Characterization of white matter damage in ischemic leukoaraiosis with diffusion tensor MRI. Stroke 1999;30:393-7.
  73. KÁRADÓTTIR R, CAVELIER P, BERGERSEN LH, ATTWELL D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005;438:1162-1166.
  74. KIERNAN RJ, MUELLER J, LANGSTON JW, VAN DYKE C. The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med 1987;107:481-5.
  75. KNOPMAN DS, PARISI JE, SALVIATI A et al. Neuropathology of cognitive normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95.
  76. LAZARUS R, PRETTYMAN R, CHERRYMAN G. White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. Int J Geriatr Psychiatry 2005;20:274-9.
  77. LE BIHAN D, MANGIN JF, POUPON C et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534-546.
  78. LEYS D, PRUVO JP, PARENT M et al. Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 1991;54:46-50.
  79. LONGSTRETH WT, JR., MANOLIO TA, ARNOLD A et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274-82.
  80. MCCARRON MO, DELONG D, ALBERTS MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999;53:1308- 1311.
  81. MEYER JS, KAWAMURA J, TERAYAMA Y. White matter lesions in the elderly. J Neurol Sci 1992;110:1-7.
  82. MORRIS JC, STORANDT M, MILLER JP et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
  83. MOSCONI L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
  84. NORDAHL CW, RANGANATH C, YONELINAS AP, DECARLI C, FLETCHER E, JAGUST WJ. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J Cogn Neurosci 2006;18:418-29.
  85. O'SULLIVAN M, SUMMERS PE, JONES DK et al. Normal-appearing white matter in ischemic leukoaraiosis: A diffusion tensor MRI study. Neurology 2001;57:2307-2310.
  86. O'SULLIVAN M, MORRIS RG, HUCKSTEP B, JONES DK, WILLIAMS SC, MARKUS HS. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 2004;75:441-7.
  87. O'SULLIVAN M. Leukoaraiosis. Pract Neurol 2008;8:26-38.
  88. OTTO M, WILTFANG J, TUMANI H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-2.
  89. PANTONI L, GARCIA JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995;26:1293-1301.
  90. PANTONI L, POGGESI A, BASILE AM et al. Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. J Am Geriatr Soc 2006;54:1095-101.
  91. PAPEZ JW. A proposed mechanism of emotion. 1937. J Neuropsychiatry Clin Neurosci 1995;7:103-112.
  92. PESKIND ER, LI G, SHOFER J et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006;63:936-9.
  93. PETERSEN RC, DOODY R, KURZ A et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
  94. PETERSEN RC, SMITH GE, WARING SC, IVNIK RJ, TANGALOS EG, KOKMEN E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
  95. PETERSEN RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
  96. PIERPAOLI C, BARNETT A, PAJEVIC S et al. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 2001;13:1174-1185.
  97. PRINS ND, VAN DIJK EJ, DEN HEIJER T et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005;128:2034-41.
  98. PRINS ND, VAN DIJK EJ, DEN HEIJER T et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004;61:1531-1534.
  99. REED BR, MUNGAS DM, KRAMER JH, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 2007;130:731-9.
  100. REISBERG B, FERRIS SH, DE LEON MJ, CROOK T. Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661-3.
  101. REISBERG B, GAUTHIER S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr 2008;20:1-16.
  102. ROHER AE, WEISS N, KOKJOHN TA et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002;41:11080-11090.
  103. ROMAN GC, SACHDEV P, ROYALL DR et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004;226:81-7.
  104. SABRI O, RINGELSTEIN EB, HELLWIG D et al. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999;30:556-66.
  105. SADOWSKI M, PANKIEWICZ J, SCHOLTZOVA H et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res 2004;29:1257-66.
  106. SALAMON G, BOUDOURESQUES J, COMBALBERT A, KHALIL R, FAURE J, GIUDICELLI G. [Lenticulo-striated arteries. Arteriographic study. Their importance in the diagnosis of intracerebral hematomas]. Rev Neurol (Paris) 1966;114:361-73.
  107. SCHELTENS P, BARKHOF F, LEYS D et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
  108. SCHWAMM LH, VAN DYKE C, KIERNAN RJ, MERRIN EL, MUELLER J. The Neurobehavioral Cognitive Status Examination: comparison with the Cognitive Capacity Screening Examination and the Mini-Mental State Examination in a neurosurgical population. Ann Intern Med 1987;107:486- 491.
  109. SELKOE DJ. Deciphering the genesis and fate of amyloid-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002;110:1375-1381.
  110. SIMPSON JE, FERNANDO MS, CLARK L et al. White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol Appl Neurobiol 2007;33:410-419.
  111. SKINNINGSRUD A, STENSET V, GUNDERSEN AS et al. Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Research 2008;5:14.
  112. SNOWDON DA, GREINER LH, MORTIMER JA, RILEY KP, GREINER PA, MARKESBERY WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama 1997;277:813-817.
  113. SODERLUND H, NILSSON LG, BERGER K et al. Cerebral changes on MRI and cognitive function: the CASCADE study. Neurobiol Aging 2006;27:16-23.
  114. SONG SK, SUN SW, JU WK, LIN SJ, CROSS AH, NEUFELD AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 2003;20:1714-1722.
  115. SONG SK, SUN SW, RAMSBOTTOM MJ, CHANG C, RUSSELL J, CROSS AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17:1429-1436.
  116. STORANDT M, GRANT EA, MILLER JP, MORRIS JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467-473.
  117. STRITTMATTER WJ, WEISGRABER KH, HUANG DY et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
  118. SUN SW, LIANG HF, CROSS AH, SONG SK. Evolving Wallerian degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging. Neuroimage 2008;40:1-10.
  119. SUN X, HE G, QING H et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006;103:18727-32.
  120. SUNDERLAND T, LINKER G, MIRZA N et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama 2003;289:2094-2103.
  121. SUSSMUTH SD, REIBER H, TUMANI H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:95-98.
  122. TAYLOR WD, BAE JN, MACFALL JR et al. Widespread effects of hyperintense lesions on cerebral white matter structure. AJR Am J Roentgenol 2007;188:1695-1704.
  123. TEODORCZUK A, O'BRIEN JT, FIRBANK MJ et al. White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry 2007;191:212-217.
  124. TEUNISSEN CE, DIJKSTRA C, POLMAN C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41.
  125. TURNER ST, FORNAGE M. Genetics of leukoaraiosis. J Stroke Cerebrovasc Dis 2002;11:241-251.
  126. ULUG AM , MOORE DF, BOJKO AS et al. Clinical Use of Diffusion-Tensor Imaging for Diseases Causing Neuronal and Axonal Damage. Am J Neuroradiol 1999;20:1044-1048.
  127. VAN STRAATEN EC, HARVEY D, SCHELTENS P et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008;255:1302-8.
  128. VAN SWIETEN JC, VAN DEN HOUT JH, VAN KETEL BA, HIJDRA A, WOKKE JH, VAN GIJN J. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. A morphometric correlation with arteriolosclerosis and dilated perivascular spaces. Brain 1991;114:761-74.
  129. VERMEER SE, PRINS ND, DEN HEIJER T, HOFMAN A, KOUDSTAAL PJ, BRETELER MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.
  130. VERNY M, DUYCKAERTS C, PIEROT L, HAUW JJ. Leuko-araiosis. Dev Neurosci 1991;13:245-250.
  131. WALSH DM, SELKOE DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-193.
  132. WANG S, WU EX, TAM CN, LAU HF, CHEUNG PT, KHONG PL. Characterization of white matter injury in a hypoxic-ischemic neonatal rat model by diffusion tensor MRI. Stroke 2008;39:2348-2353.
  133. WARD NS, BROWN MM. LEUKOARAIOSIS. IN: DONNAN GA, NORRVING B., BAMFORD J, BOGOUSSLASKY J., editors. Subcortical Stroke. 2nd ed. Oxford: Oxford University Press; 2002. p. 47-66.
  134. WINBLAD B, PALMER K, KIVIPELTO M et al. Mild cognitive impairment-- beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240- 246.
  135. WISNIEWSKI T, GOLABEK A, MATSUBARA E, GHISO J, FRANGIONE B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 1993;192:359-365.
  136. XUE R, VAN ZIJL PC, CRAIN BJ, SOLAIYAPPAN M, MORI S. In vivo three- dimensional reconstruction of rat brain axonal projections by diffusion tensor imaging. Magn Reson Med 1999;42:1123-1127.
  137. YIP AG, MCKEE AC, GREEN RC et al. APOE, vascular pathology, and the AD brain. Neurology 2005;65:259-265.
  138. ZHANG Y, SCHUFF N, JAHNG GH et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007;68:13-19.
  139. ZHOU Y, DOUGHERTY JH JR, HUBNER KF et al. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement 2008;4:265-270.

Cited by

Sorted by citations

Related

Authors
Stenset, V., Johnsen, L., Kocot, D., Negaard, A., Skinningsrud, A., Gulbrandsen, P., Wallin, A., & Fladby, T.
Affiliations
University of Oslo (NO)
ORCID
Fladby, T.
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-09-12
Volume
67
Issue
5
Pages
830-833
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/01.wnl.0000234030.77831.5a
OpenAlex
W2165815203
Cited by
44
References
46
Citations by year
2025: 1 · 2024: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
2.12
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
Keywords
white matter lesions, cerebrovascular risk factors, CSF amyloid-beta 42, Alzheimer's disease, hypertension, hyperhomocysteinemia, hypercholesterolemia, APOE ε4, subjective memory impairment, cerebrovascular disease
MeSH terms
Adult, Aged, Alzheimer Disease, Brain, Brain Injuries, Cerebrovascular Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Memory Disorders, Middle Aged, Models, Biological, Risk Factors, Severity of Illness Index, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review